Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains
dc.contributor.author | Maiti, Atanu | |
dc.contributor.author | Myint, Wazo | |
dc.contributor.author | Delviks-Frankenberry, Krista A. | |
dc.contributor.author | Hou, Shurong | |
dc.contributor.author | Kanai, Tapan | |
dc.contributor.author | Balachandran, Vanivilasini | |
dc.contributor.author | Sierra Rodriguez, Christina | |
dc.contributor.author | Tripathi, Rashmi | |
dc.contributor.author | Yilmaz, Nese Kurt | |
dc.contributor.author | Pathak, Vinay K. | |
dc.contributor.author | Schiffer, Celia A. | |
dc.contributor.author | Matsuo, Hiroshi | |
dc.date | 2022-08-11T08:10:52.000 | |
dc.date.accessioned | 2022-08-23T17:23:11Z | |
dc.date.available | 2022-08-23T17:23:11Z | |
dc.date.issued | 2020-11-20 | |
dc.date.submitted | 2021-01-06 | |
dc.identifier.citation | <p>Maiti A, Myint W, Delviks-Frankenberry KA, Hou S, Kanai T, Balachandran V, Sierra Rodriguez C, Tripathi R, Kurt Yilmaz N, Pathak VK, Schiffer CA, Matsuo H. Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains. J Mol Biol. 2020 Nov 20;432(23):6042-6060. doi: 10.1016/j.jmb.2020.10.020. Epub 2020 Oct 22. PMID: 33098858; PMCID: PMC7771068. <a href="https://doi.org/10.1016/j.jmb.2020.10.020">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 0022-2836 (Linking) | |
dc.identifier.doi | 10.1016/j.jmb.2020.10.020 | |
dc.identifier.pmid | 33098858 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/48900 | |
dc.description.abstract | APOBEC3G (A3G) is a single-stranded DNA (ssDNA) cytosine deaminase that can restrict HIV-1 infection by mutating the viral genome. A3G consists of a non-catalytic N-terminal domain (NTD) and a catalytic C-terminal domain (CTD) connected by a short linker. While the CTD catalyzes cytosine deamination, the NTD is believed to provide additional affinity for ssDNA. Structures of both A3G domains have been solved individually; however, a full-length A3G structure has been challenging. Recently, crystal structures of full-length rhesus macaque A3G variants were solved which suggested dimerization mechanisms and RNA binding surfaces, whereas the dimerization appeared to compromise catalytic activity. We determined the crystal structure of a soluble variant of human A3G (sA3G) at 2.5 A and from these data generated a model structure of wild-type A3G. This model demonstrated that the NTD was rotated 90 degrees relative to the CTD along the major axis of the molecule, an orientation that forms a positively charged channel connected to the CTD catalytic site, consisting of NTD loop-1 and CTD loop-3. Structure-based mutations, in vitro deamination and DNA binding assays, and HIV-1 restriction assays identify R24, located in the NTD loop-1, as essential to a critical interaction with ssDNA. Furthermore, sA3G was shown to bind a deoxy-cytidine dinucleotide near the catalytic Zn(2+), yet not in the catalytic position, where the interactions between deoxy-cytidines and CTD loop-1 and loop-7 residues were different from those formed with substrate. These new interactions suggest a mechanism explaining why A3G exhibits a 3' to 5' directional preference in processive deamination. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33098858&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.relation.url | https://doi.org/10.1016/j.jmb.2020.10.020 | |
dc.subject | APOBEC3G | |
dc.subject | HIV-1 restriction | |
dc.subject | co-crystal structure | |
dc.subject | cytosine deaminase | |
dc.subject | ssDNA binding | |
dc.subject | Biochemistry | |
dc.subject | Enzymes and Coenzymes | |
dc.subject | Medicinal Chemistry and Pharmaceutics | |
dc.subject | Medicinal-Pharmaceutical Chemistry | |
dc.subject | Molecular Biology | |
dc.subject | Structural Biology | |
dc.subject | Virology | |
dc.subject | Viruses | |
dc.title | Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains | |
dc.type | Journal Article | |
dc.source.journaltitle | Journal of molecular biology | |
dc.source.volume | 432 | |
dc.source.issue | 23 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/schiffer/44 | |
dc.identifier.contextkey | 20950696 | |
html.description.abstract | <p>APOBEC3G (A3G) is a single-stranded DNA (ssDNA) cytosine deaminase that can restrict HIV-1 infection by mutating the viral genome. A3G consists of a non-catalytic N-terminal domain (NTD) and a catalytic C-terminal domain (CTD) connected by a short linker. While the CTD catalyzes cytosine deamination, the NTD is believed to provide additional affinity for ssDNA. Structures of both A3G domains have been solved individually; however, a full-length A3G structure has been challenging. Recently, crystal structures of full-length rhesus macaque A3G variants were solved which suggested dimerization mechanisms and RNA binding surfaces, whereas the dimerization appeared to compromise catalytic activity. We determined the crystal structure of a soluble variant of human A3G (sA3G) at 2.5 A and from these data generated a model structure of wild-type A3G. This model demonstrated that the NTD was rotated 90 degrees relative to the CTD along the major axis of the molecule, an orientation that forms a positively charged channel connected to the CTD catalytic site, consisting of NTD loop-1 and CTD loop-3. Structure-based mutations, in vitro deamination and DNA binding assays, and HIV-1 restriction assays identify R24, located in the NTD loop-1, as essential to a critical interaction with ssDNA. Furthermore, sA3G was shown to bind a deoxy-cytidine dinucleotide near the catalytic Zn(2+), yet not in the catalytic position, where the interactions between deoxy-cytidines and CTD loop-1 and loop-7 residues were different from those formed with substrate. These new interactions suggest a mechanism explaining why A3G exhibits a 3' to 5' directional preference in processive deamination.</p> | |
dc.identifier.submissionpath | schiffer/44 | |
dc.contributor.department | Schiffer Lab | |
dc.contributor.department | Department of Biochemistry and Molecular Pharmacology | |
dc.source.pages | 6042-6060 |